Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial

Further Publications

Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: Pooled analysis of the CAO/ARO/AIO-12 and the OPRA randomized phase 2 trials

Eur J Cancer

Fokas E, Williams H, Diefenhardt M, Lin S, Qin LX, Piso P, Dapper H, Germer CT, Grützmann R, Tim Friede J, Joshua Smith J, Saltz LB, Wu AJ, Weiser MR, Omer D, Ghadimi M, Hofheinz RD, Garcia-Aguilar J, Rödel C, German Rectal Cancer Study Group and the OPRA Consortium

doi: 10.1016/j.ejca.2024.114291

Gastrointestinal Cancer

Induction treatment with FOLFIRINOX or oxaliplatin-based doublet followed by long-course chemoradiotherapy and surgery in locally advanced rectal cancer. A systematic review and pooled analysis from phase II and III trials

Cancer Treat Rev

Moretto R, Vetere G, Carullo M, Ciracì P, Masi G, Cremolini C

doi: 10.1016/j.ctrv.2024.102829

Gynecologic Cancer

Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial

Lancet

McCormack M, Eminowicz G, Gallardo D, Diez P, Farrelly L, Kent C, Hudson E, Panades M, Mathew T, Anand A, Persic M, Forrest J, Bhana R, Reed N, Drake A, Adusumalli M, Mukhopadhyay A, King M, Whitmarsh K, McGrane J, Colombo N, Mak C, Mandal R, Chowdhury RR, Alamilla-Garcia G, Chávez-Blanco A, Stobart H, Feeney A, Vaja S, Hacker AM, Hackshaw A, Ledermann JA, INTERLACE investigators

doi: 10.1016/S0140-6736(24)01438-7

Breast Cancer

Optimizing treatment sequence for inoperable locally advanced breast cancer: Long-term outcomes of surgery first versus neoadjuvant chemotherapy in a real-world setting

Int J Cancer

Liu B, Song Y, Xu Y, Sun Q, Zhou Y, Lin Y

doi: 10.1002/ijc.35140

Gastrointestinal Cancer

Neoadjuvant Treatment With Regorafenib and Capecitabine Combined With Radiotherapy in Locally Advanced Rectal Cancer: A Multicenter Phase Ib Trial (RECAP)-SAKK 41/16

Clin Colorectal Cancer

Bastian S, Joerger M, Holer L, Bärtschi D, Guckenberger M, Jochum W, Koeberle D, Siebenhüner AR, Wicki A, Berger MD, Winterhalder RC, Largiadèr CR, Löffler M, Mosna-Firlejczyk K, Maranta AF, Pestalozzi BC, Csajka C, von Moos R, Swiss Group for Clinical Cancer Research (SAKK)

doi: 10.1016/j.clcc.2024.10.002

Breast Cancer

Differential long-term tamoxifen therapy benefit by menopausal status in breast cancer patients: secondary analysis of a controlled randomized clinical trial

J Natl Cancer Inst

Johansson A, Dar H, Nordenskjöld A, Perez-Tenorio G, Tobin NP, Yau C, Benz CC, Esserman LJ, van 't Veer LJ, Nordenskjöld B, Stål O, Fornander T, Lindström LS

doi: 10.1093/jnci/djae268

ESMO 2024

Gynecologic Cancer

KEYNOTE-A18: Pembrolizumab plus chemoradiotherapy improves PFS and OS in patients with high-risk, locally advanced cervical cancer

RECOMMENDED

Breast Cancer

Impact of loss of HER2 positivity following neoadjuvant therapy in HER2-positive breast cancer patients on long-term prognosis: A systematic review and meta-analysis

★ 2 Recommended by Prof. Dr Beat Thürlimann, Faculty Member

Cancer Treat Rev

Nakatani S, Hayashi T, Yamamoto K, Maeda H

doi: 10.1016/j.ctrv.2025.102923

COMMENTED

Gynecologic Cancer

Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from PRIMA/ENGOT-OV26/GOG-3012 trial

★ 0 Recommended and commented by Prof. Dr Beat Thürlimann, Faculty Member

Ann Oncol

Monk BJ, Barretina-Ginesta MP, Pothuri B, Vergote I, Graybill W, Mirza MR, McCormick CC, Lorusso D, Moore RG, Freyer G, O'Cearbhaill RE, Heitz F, O'Malley DM, Redondo A, Shahin MS, Vulsteke C, Bradley WH, Haslund CA, Chase DM, Pisano C, Holman LL, Pérez MJR, DiSilvestro P, Gaba L, Herzog TJ, Bruchim I, Compton N, Shtessel L, Malinowska IA, González-Martín A

doi: 10.1016/j.annonc.2024.08.2241

Related content

Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: Pooled analysis of the CAO/ARO/AIO-12 and the OPRA randomized phase 2 trials

Induction treatment with FOLFIRINOX or oxaliplatin-based doublet followed by long-course chemoradiotherapy and surgery in locally advanced rectal cancer. A systematic review and pooled analysis from phase II and III trials

Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial

Optimizing treatment sequence for inoperable locally advanced breast cancer: Long-term outcomes of surgery first versus neoadjuvant chemotherapy in a real-world setting

Neoadjuvant Treatment With Regorafenib and Capecitabine Combined With Radiotherapy in Locally Advanced Rectal Cancer: A Multicenter Phase Ib Trial (RECAP)-SAKK 41/16

Differential long-term tamoxifen therapy benefit by menopausal status in breast cancer patients: secondary analysis of a controlled randomized clinical trial

KEYNOTE-A18: Pembrolizumab plus chemoradiotherapy improves PFS and OS in patients with high-risk, locally advanced cervical cancer

Impact of loss of HER2 positivity following neoadjuvant therapy in HER2-positive breast cancer patients on long-term prognosis: A systematic review and meta-analysis

Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from PRIMA/ENGOT-OV26/GOG-3012 trial